LNK01002 / Lynk Pharmaceuticals - LARVOL DELTA

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Lynk Pharmaceuticals Co., Ltd | N=93 ➔ 0 | Trial completion date: Dec 2023 ➔ Oct 2022 | Recruiting ➔ Withdrawn | Trial primary completion date: Oct 2023 ➔ Oct 2022

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Thrombocytosis

Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002 (PRNewswire) - “Lynk Pharmaceuticals…announced today that it has administered its triple-kinase inhibitor LNK01002 to the first patient in a phase I clinical trial. This is a multi-center, open label phase I clinical study to evaluate the safety, tolerance and pharmacokinetics of LNK01002 in patients with primary myelofibrosis (PMF) and secondary myelofibrosis (PV/ET-MF) induced by polycythemia vera or primary thrombocytosis.”

Trial status • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera

A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia (clinicaltrials.gov) - P1; N=93; Recruiting; Sponsor: Lynk Pharmaceuticals Co., Ltd

Clinical • New P1 trial • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology • Polycythemia Vera • Thrombocytosis • MRI